17beta-estradiol downregulates angiotensin-II-induced endothelin-1 gene expression in rat aortic smooth muscle cells. 2004

Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
School of Chinese Medicine, China Medical University, Taichung, Taiwan, ROC.

It is well documented that 17beta-estradiol (E(2)) exerts a cardiovascular protective effect. A possible role of E(2) in the regulation of endothelin-1 (ET-1) production has been reported. However, the complex mechanisms by which E(2) inhibits ET-1 expression are not completely understood. The aims of this study were to examine whether E(2) may alter angiotensin II (Ang II)-induced cell proliferation and ET-1 gene expression and to identify the putative underlying signaling pathways in rat aortic smooth muscle cells. Cultured rat aortic smooth muscle cells were preincubated with E(2), then stimulated with Ang II, and [(3)H]thymidine incorporation and ET-1 gene expression were examined. The effect of E(2) on Ang-II-induced extracellular signal-regulated kinase (ERK) phosphorylation was tested to elucidate the intracellular mechanism of E(2) in proliferation and ET-1 gene expression. Ang II increased DNA synthesis which was inhibited with E(2) (1- 100 nM). E(2), but not 17alpha-estradiol, inhibited the Ang-II-induced ET-1 gene expression as revealed by Northern blotting and promoter activity assay. This effect was prevented by coincubation with the estrogen receptor antagonist ICI 182,780 (1 microM). E(2) also inhibited Ang-II-increased intracellular reactive oxygen species (ROS) as measured by a redox-sensitive fluorescent dye, 2',7'-dichlorofluorescin diacetate, and ERK phosphorylation. Furthermore, E(2) and antioxidants, such as N-acetyl cysteine and diphenylene iodonium, decreased Ang-II-induced cell proliferation, ET-1 promoter activity, ET-1 mRNA, ERK phosphorylation, and activator protein-1-mediated reporter activity. In summary, our results suggest that E(2) inhibits Ang-II-induced cell proliferation and ET-1 gene expression, partially by interfering with the ERK pathway via attenuation of ROS generation. Thus, this study provides important new insight regarding the molecular pathways that may contribute to the proposed beneficial effects of estrogen on the cardiovascular system.

UI MeSH Term Description Entries
D008297 Male Males
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D002455 Cell Division The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION. M Phase,Cell Division Phase,Cell Divisions,Division Phase, Cell,Division, Cell,Divisions, Cell,M Phases,Phase, Cell Division,Phase, M,Phases, M
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000975 Antioxidants Naturally occurring or synthetic substances that inhibit or retard oxidation reactions. They counteract the damaging effects of oxidation in animal tissues. Anti-Oxidant,Antioxidant,Antioxidant Activity,Endogenous Antioxidant,Endogenous Antioxidants,Anti-Oxidant Effect,Anti-Oxidant Effects,Anti-Oxidants,Antioxidant Effect,Antioxidant Effects,Activity, Antioxidant,Anti Oxidant,Anti Oxidant Effect,Anti Oxidant Effects,Anti Oxidants,Antioxidant, Endogenous,Antioxidants, Endogenous

Related Publications

Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
May 2005, European journal of pharmacology,
Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
October 2005, Clinical and experimental pharmacology & physiology,
Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
July 2008, Arteriosclerosis, thrombosis, and vascular biology,
Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
September 2004, American journal of physiology. Heart and circulatory physiology,
Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
April 2001, Hypertension (Dallas, Tex. : 1979),
Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
November 1998, Circulation research,
Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
August 2001, Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology,
Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
September 2009, Atherosclerosis,
Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
February 1994, Molecular endocrinology (Baltimore, Md.),
Hong-Jye Hong, and Ju-Chi Liu, and Paul Chan, and Shu-Hui Juan, and Shih-Hurng Loh, and Jaung-Geng Lin, and Tzu-Hurng Cheng
June 2004, Sheng li xue bao : [Acta physiologica Sinica],
Copied contents to your clipboard!